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Objectives: Mechanisms of resistance to ethambutol in Mycobacterium tuberculosis remain inadequately
described. Although there is mounting evidence that mutations of codon 306 in embB play a key role, a signiﬁ-
cant number of phenotypically ethambutol-resistant strains do not carry mutations in this codon. Here, other
mutations in the embCAB operon are suggested to be involved in resistance development.
Methods: The entire embCAB operon ( 10 kb) was analysed in 34 phenotypically ethambutol-resistant
M. tuberculosis strains without mutations in embB306 and in 12 ethambutol-susceptible strains. Furthermore,
106 control strains were investigated for the presence of particular mutations only.
Results: Overall, 18 non-synonymous mutations in 15 distinct codons of the embCAB operon were identiﬁed in
ethambutol-resistant strains but not in ethambutol-susceptible isolates. The majority occurred in the embB
gene (10 distinct codons), in a 570 bp region also encompassing embB306. Mutations in embC and embA
were found rarely and in most cases in combination with polymorphisms in embB. One synonymous mutation
(embA 228 bp) and two non-synonymous mutations (embCVal981Leu and embCArg738Gln) were found in
ethambutol-susceptible strains as well as resistant strains and were conﬁrmed to represent phylogenetic
markers for strains of the Beijing, Haarlem and Delhi/CAS genotypes, respectively.
Conclusions: Besides mutations in embB306, mutations in embB406 and embB497 were conﬁrmed as hot
spots for genomic variation in ethambutol-resistant clinical isolates. Of all resistant strains 70.6% carry a
mutation in a relatively short region in embB, which therefore represents a promising target for inclusion in
molecular assays for rapid detection of ethambutol resistance.
Keywords: resistance testing, new mutations, genotyping, phylogenetic markers, Beijing genotype
Introduction
The worldwide emergence of drug-resistant Mycobacterium
tuberculosis complex (MTBC) strains complicates the treatment
of patients suffering from tuberculosis (TB). In particular
multidrug-resistant (MDR) and extensively drug-resistant (XDR)
TB represents a serious challenge for TB control.
1
The rapid detection of drug resistance is essential to design
appropriate treatment regimens, prevent treatment failure and
thus reduce the further spread of drug-resistant isolates. While
the development of liquid media-based systems has reduced
turnaround times for drug susceptibility testing, molecular
assays (e.g. line-probe assays like GenoType MTBDR; Hain
Lifescience, Nehren, Germany) have the potential to dramatically
reduce delay. However, these molecular assays require precise
knowledge of the genetic variation involved in the development
of resistance to particular anti-TB drugs.
Ethambutol is a key component in anti-TB therapy. Previous
studies suggest that 69% of ethambutol-resistant M. tuberculosis
strains carry a mutation in the embB gene, mutations in codon
embB306 occurring most frequently.
2 Consequently mutations
in this codon have been suggested as molecular markers for
the rapid detection of ethambutol resistance.
3–6 Furthermore,
two recent studies demonstrated a clear causative relationship
between embB306 point mutations and in vitro ethambutol
resistance by allelic-exchange experiments.
7,8
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 However, approximately one-third of ethambutol-resistant
clinical isolates do not carry a mutation in embB306 and are
therefore not detectable by using molecular methods based
on the determination of polymorphisms in embB306 only
(e.g. DNA sequencing, real-time PCR or strip technologies).
Although other mutations in the embCAB operon are suggested
to confer resistance, only limited data have been available until
now, with most studies analysing only a short fragment of the
embB gene encompassing codon 306.
2,3,5,9,10
To add further data to this important question we sequenced
the entire embCAB operon from isolates phenotypically etham-
butol resistant, but lacking a mutation in embB306, that were
identiﬁed from previous investigations. These were compared
with ethambutol-susceptible isolates included as controls.
Materials and methods
M. tuberculosis clinical isolates
A total of 152 clinical M. tuberculosis isolates were included in this study.
The strain collection for analysis of the entire embCAB operon consisted
of 30 (24 ethambutol resistant and 6 ethambutol susceptible) clinical
M. tuberculosis isolates obtained from patients in Germany and 16 (10
ethambutol resistant and 6 ethambutol susceptible) from patients in
Uzbekistan. The ethambutol-resistant strains were previously identiﬁed
as having no mutations in codon embB306. To assess the signiﬁcance
of particular mutations for ethambutol resistance, 106 additional
strains (104 ethambutol susceptible and 2 ethambutol resistant) col-
lected during 1 year (2007) in Hamburg, Germany, were analysed for
the presence of speciﬁc mutations.
Drug susceptibility testing
For all strains, resistance to the key antimycobacterial drugs isoniazid,
rifampicin, ethambutol and streptomycin was determined. Resistance
determination for isoniazid, rifampicin, ethambutol and streptomycin
was performed by using the proportion method on Lo ¨wenstein–Jensen
(LJ) medium (critical concentration used for ethambutol was 2.0 mg/L).
If growth was insufﬁcient, drug susceptibility testing was performed by
using the modiﬁed proportion method in BACTEC 460TB (Becton-
Dickinson; critical concentration used for ethambutol was 3.75 mg/L) or
Bactec MGIT 960 system (5.0 mg/L for ethambutol).
IS6110 proﬁling and spoligotyping
Extraction of genomic DNA from mycobacterial strains and DNA ﬁnger-
printing using IS6110 as a probe were performed according to a standar-
dized protocol as described previously.
11 Additionally, all isolates were
analysed by the spoligotyping technique as described previously by
Kamerbeek et al.
12 The molecular typing data were analysed using the
Bionumerics software (version 5.1; Applied Maths, Sint-Martens-Latem,
Belgium) as instructed by the manufacturer. Spoligotyping data were
used to additionally conﬁrm strain relationships and for identiﬁcation of
Beijing genotype isolates (no hybridization to spacers 1–34, hybridization
to spacers 35–43).
PCR ampliﬁcation and sequencing strategy
The 34 ethambutol-resistant as well as the 12 ethambutol-susceptible
clinical M. tuberculosis isolates were sequenced in the whole embCAB
operon. The 106 strains collected in Hamburg in 2007 were analysed
with regard to embCArg738Gln as well as nucleotides 28, 212, 216,
225 and 232 in the embCA intergenic region. Furthermore the embB
region encompassing codons 306–497 was analysed. DNA ampliﬁcation
was performed using the primers and conditions listed in Table 1. The PCR
products obtained were sequenced using an ABI Prism 3130xl Genetic
Analyser (Applied Biosystems, CA, USA) and the ABI Prism BigDye Termin-
ator Kit v.3.1, according to the manufacturer’s instructions. Analysis of
sequence data was performed using SeqScape v2.6 software.
Results
The entire embCAB operon ( 10 kb) of 34 ethambutol-resistant
and 12 ethambutol-susceptible clinical M. tuberculosis isolates
was sequenced. All ethambutol-resistant strains showed
additional resistance at least to isoniazid, rifampicin and strepto-
mycin (n¼25) or isoniazid and streptomycin (n¼9). Overall 33
different mutations, non-synonymous (resulting in an amino
acid replacement) as well as synonymous (no amino acid repla-
cement), were identiﬁed in embCAB of resistant strains only
(Table 2). Most mutations occurred in embB outside of codon
embB306 (13 non-synonymous and three synonymous
mutations). The remaining regions of the operon were less fre-
quently affected; seven mutations in embA (three non-
synonymous and four synonymous mutations), six nucleotide
variations in the embC–embA intergenic region and four
mutations in embC (three non-synonymous and one synon-
ymous mutation). A total of 26 ethambutol-resistant strains
carried at least one mutation resulting in an amino acid replace-
ment. Only three ethambutol-resistant isolates did not show any
mutations across the entire operon. Three mutations occurred in
resistant and susceptible isolates and are more likely to be phy-
logenetic rather than resistance markers.
In the following sections, the mutations detected in resistant
strains only (Figures 1 and 2 and Table 2) as well as the
mutations found in both resistant and susceptible isolates (phy-
logenetic markers; Figure 3) are presented in detail.
Polymorphisms in the embC gene
In the embC gene three non-synonymous mutations, possibly
associated with ethambutol resistance, were identiﬁed in four
ethambutol-resistant strains (see Table 2). Two strains had an
amino acid replacement located in codon 738. Amino acid
changes in embC in codons 270 and 406 were found in one
isolate each. One of the strains with Arg738Gln replacement as
well as the strain with Thr270Ile also had other mutations in
embCAB resulting in amino acid changes. These additional
mutations in embA, embB and the embCA intergenic region
were also exclusively found in ethambutol-resistant isolates
(see Table 2). One ethambutol-resistant isolate had a silent
mutation at nucleotide position 1239 bp. Furthermore,
one ethambutol-susceptible isolate showed a mutation at
codon 102.
Polymorphisms in the embC–embA intergenic region
Nine ethambutol-resistant isolates had nucleotide changes
located in the embC–embA intergenic region (see Table 2 and
Figure 1). In four ethambutol-resistant strains a nucleotide sub-
stitution was identiﬁed at position 212 bp, but this mutation was
also present in one ethambutol-susceptible isolate. The other
nucleotide variations in the intergenic region were found in
Plinke et al.
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 resistant isolates only and occurred at positions 28, 216, 225
and 232 bp. In one strain no other mutation in embCAB
was identiﬁed, so this single nucleotide polymorphism (SNP)
at 28 bp might confer ethambutol resistance.
Polymorphisms in the embA gene
Three ethambutol resistance-associated amino acid replace-
ments were identiﬁed in two isolates (see Table 2 and Figure 1).
One of these isolates carried two non-synonymous mutations
located in codons 468 and 639. Furthermore a silent mutation in
embA at position 988 bp was detected in this strain as well.
Another isolate carried a mutation at codon 576. Three isolates
had a silent mutation in embA at positions 1851, 1995 and
2124 bp, respectively. All strains, but one, carrying a mutation in
embA had additional mutations in embB, embC or the intergenic
region (see Table 2). In the ethambutol-susceptible isolates no
resistance-associated mutations were detected in embA (except
the phylogenetic markers discussed below).
Polymorphisms in the embB gene
The embB gene was most frequently affected by mutations
resulting in amino acid exchanges. Overall non-synonymous
Table 1. PCR primers and conditions used for ampliﬁcation and sequencing
Primer Primer sequence (5′ 3′) Size (bp)
PCR conditions
a
D (s) A (8C, s) E (s)
Rv3795anewF CTG GGG ATC GGT GGA GCA GTA 969 30 66.0, 45 60
Rv3795anewR GCG TCG GTC AGG GTG AAG G
Rv3795bF TGG ACG GGC GGG GCT CAA T 1306 60 65.0, 60 90
Rv3795bcR GCA AAC AGG GCG AAA AAG A
Rv3795cF TCC TGG CGG CGT TAT TCT T 1653 60 65.0, 60 90
Rv3795cS1
b TGG ACG GCG ATT CGG GTT CT
Rv3795cS2
b GGA CTG GGC GGT CGG TTT G
Rv3795cR CAA CCG GGG TGA TGA TGG C
embIR-F
c CTG GTG GTC GCG GTG ATC AT 907 30 64.0, 45 60
embIR-newR ACG GTC GCT GGC AGG GGA AGT T
embIR-newF CGC CTA TGA CCC GAA CCT GAG 787 30 65.0, 45 60
embIR-R
c AAT TGG CGT CCT TGC CTT
embA1-F
c GTG ACT CGC AGC GGG CTG TG 1223 30 68.0, 30 90
embA1-R
c CGG TGA ACA CAG CGA CCC GG
embA2-F
c TGG ACC GGC TCA GCA GGG G 1500 30 67.0, 30 90
embA2-R
c TCA GGT TGG CCT TGG CGG TG
embC1-F
c CCC AAC CAG CCC AAT GTT C 890 40 64.5, 30 60
embC1-R
c GGC GGT GTC CAG GAT GTG
embC2-F
c GCT GCA CAT CCT GGA CAC 914 40 60.0, 30 60
embC2-R
c ACG ACA TTG CCA CCG ATA C
embC3-F
c GTA TCG GTG GCA ATG TCG T 1176 40 60.0, 30 60
embC3-R
c CGG GAT GGC GGA CAG TGG T
embC4-F
c ACC ACT GTC CGC CAT CCC G 635 30 67.0, 30 45
embC4-R
c GAC GAC GGC TGC TAG GCG TG
embC1-F2 GAA GCC GCC CCA CCC CGT ATC G 996 30 68.0, 45 60
embC1-R2 AGC CCA CAG CGC CAG CAG GTC GTA
embC2-F2 GCG GGC ATG TTT CTG GCT GTC TGG 1058 30 64.0, 45 60
embC2-R2 CAC GCC GGG TAC TGG GAA ATC ATC
embC3-F2 CGC GCC CGG CTG CCC TAC AAC 464 30 68.0, 45 60
embC3-R2 GCC AGC CCC ACC AGC CAG TCC A
embC_5′ (+2002) CTG ACG GTG CTG GTG CTG CTG CTA 372 30 65.0, 30 30
embC_3′ (+2373) GGG AAT GCC GTT GGG TGT GAA GG
embCA_5′ (+3134) TGG CCA GCT ACC TCA AAG ACG ACT 437 30 60.0, 30 30
embCA_3′ (+200) GGC GCC CCG GAT ACC AGA
aD,lengthof denaturation at948C;A,primerannealingconditions(temperaturein 8Cand lengthin s);
E,lengthofextensionat728C.AllPCRswere35cycles,wereprecededbyaninitialdenaturationstepat
958C for 15 min and included a ﬁnal extension step at 728C for 5 min.
bSequencing primer.
cSee Ramaswamy et al.
15
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 mutations in 10 distinct codons were found in 24 ethambutol-
resistant isolates (see Table 2 and Figure 2). Three isolates even
had two amino acid replacements in embB (see Table 2). One
of these three strains also had a silent mutation at position
2982 bp. Silent mutations at positions 1995 and 3081 bp,
respectively, were also identiﬁed in two isolates. The majority
of the mutations were detected in embB406 (n¼8) and
embB497 (n¼10). No mutations in embB were detected
among ethambutol-susceptible isolates.
Combination of mutations
Overall nine isolates had more than one mutation in the embCAB
region (see Table 2). In one isolate seven different mutations
were detected; one non-synonymous mutation in embC and
two non-synonymous mutations and one synonymous mutation
in both embA and embB. Four strains were found to have two
mutations resulting in an amino acid exchange. In two of
these strains both mutations occurred in embB and the other iso-
lates carried one mutation in embB as well as one in embA and
embC, respectively. The other four strains had synonymous
mutations or nucleotide variations in the intergenic region in
addition to a non-synonymous mutation in embB.
Genotype-speciﬁc SNPs
Overall, three different mutations were found in both susceptible
and resistant isolates and, thus, are potentially not involved in
ethambutol resistance. In 22 ethambutol-resistant clinical iso-
lates a synonymous mutation at nucleotide position 228 bp in
embA was detected (see Figure 3). This mutation also occurred
in six ethambutol-susceptible strains, suggesting that it might
be a phylogenetic marker. A dendrogram calculated on the
basis of IS6110 DNA ﬁngerprint and spoligotyping analyses
revealed that all strains carrying the mutation at position
228 bp in embA belong to the Beijing genotype (Figure 3).
Interestingly, nine of the Beijing strains that formed a sub-group
within the Beijing branch had an additional mutation at position
114 bp in embA. Furthermore an amino acid replacement
in embC at codon 981 was preferentially found in Haarlem
genotype strains and might be speciﬁc for this phylogenetic
lineage.
Table 2. Mutations detected in the embCAB operon of the 34 investigated ethambutol-resistant clinical M. tuberculosis isolates
a
Total number of strains
Mutations in embCAB
embC intergenic region embCA embA embB
1c  T, 809 bp (Thr270Ile) — c T, 988 bp (silent) a C, 1133 bp (Glu378Ala)
t C, 1403 bp (Val468Ala) g A, 1216 bp (Gly406Ser)
c T, 1915 bp (Pro639Ser) c T, 2982 bp (silent)
1a  G, 1216 bp (Ile406Val) — — —
1g  A, 1239 bp (silent) deletion G, 232 bp — a G, 1490 bp (Gln497Arg)
1g  A, 2213 bp (Arg738Gln)
b —— —
1g  A, 2213 bp (Arg738Gln)
b deletion A, 225 bp — g A, 1217 bp (Gly406Asp)
1— c  A, 28b p — —
1— c  T, 28b p g  A, 1726 bp (Ala576Thr) a G, 1490 bp (Gln497Arg)
3— c  T, 212 bp — —
1— c  T, 212 bp — g A, 1060 bp (Asp354Asn)
g A, 3081 bp (silent)
1— c  T, 216 bp c T, 2124 bp (silent) g C, 1217 bp (Gly406Ala)
g A, 1995 bp (silent)
1— —a  G, 1851 bp (silent) g A, 1217 bp (Gly406Asp)
1— —c  T, 1995 bp (silent) —
1— —— t  G, 221 bp (Leu74Arg)
a G, 983 bp (Asp328Gly)
1— —— t  G, 221 bp (Leu74Arg)
g A, 1360 bp (Ala454Thr)
1— —— c  G, 1204 bp (Leu402Val)
1— —— c  T, 1210 bp (Pro404Ser)
3— —— g  A, 1217 bp (Gly406Asp)
1— —— g  C, 1217 bp (Gly406Ala)
1— —— c  G, 1350 bp (Ile450Met)
1— —— c  A, 1489 bp (Gln497Lys)
7— —— a  G, 1490 bp (Gln497Arg)
3— —— —
aOther phylogenetic mutations have been excluded from this table.
bThe R738Q mutation has been identiﬁed as a phylogenetic marker for the Delhi/CAS genotype.
Plinke et al.
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 The mutation in embC at codon 738 occurred in two
ethambutol-resistant isolates. In one of those two strains this
mutation was the only mutation detected in the whole embCAB
operon, suggesting this SNPas a resistance-mediating polymorph-
ism. However, IS6110 DNA ﬁngerprint and spoligotyping analyses
showed that both strains belong to the Delhi/CAS genotype.
g>A, 1216 bp (G406S), n = 1
g>C, 1217 bp (G406A), n = 2
a>G, 1490 bp (Q497R), n = 9
c>A, 1489 bp (Q497K), n = 1
g>A, 1360 bp (A454T), n = 1
c>G, 1350 bp (I450M), n = 1
a>G, 983 bp (D328G), n = 1
g>A, 1060 bp (D354N), n = 1
g>A, 1217 bp (G406D), n = 5
c>T, 1210 bp (P404S), n = 1
c>G, 1204 bp (L402V), n = 1
t>G, 221 bp (L74R), n = 2
a>C, 1133 bp (E378A), n = 1
embB (3297 bp)
embB306
Figure 2. Non-synonymous mutations detected in the embB gene of the 34 ethambutol-resistant clinical M. tuberculosis isolates analysed. Overall, 24
of the ethambutol-resistant strains carried a mutation in embB resulting in an amino acid exchange. In three strains more than one non-synonymous
mutation was found. The previously described hot spot codon embB306 is marked in a box. Exchange of the base pairs as well as of the amino acids
and the positions of nucleotides are indicated. The total number of strains in which the speciﬁc mutation was detected is also given.
c>T, 809 bp (T270I), n = 1
a>G, 1216 bp (I406V), n = 1
t>C, 1403 bp (V468A), n = 1
g>A, 1726 bp (A576T), n = 1
c>T, 1915 bp (P639S), n = 1
embC (3285 bp) embA (3285 bp)
Intergenic region embCA (85 bp)
c>T/A, – 8 bp, n = 1/n = 1
c>T, – 12 bp, n = 4
c>T, – 16 bp, n = 1
deletion A, – 25 bp, n = 1
deletion G, – 32 bp, n = 1
Figure 1. Non-synonymous mutations detected in embC and embA as well as in the intergenic region of the 34 ethambutol-resistant clinical
M. tuberculosis isolates analysed. Two different mutations were found in embC. Out of the two embC mutants one isolate had no other mutation
in the entire embCAB operon. In the embA gene three different mutations were found. Two of these mutations (V468A and P639S) occurred in
one isolate. All of the embA mutants had additional mutations in embC, embB and/or the intergenic region embCA. Six different mutations in the
intergenic region were identiﬁed in nine isolates of which two had no other mutations. Exchange of the base pairs as well as of the amino acids
and the positions of nucleotides are indicated. The total number of strains in which the speciﬁc mutation was detected is also given.
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 Haarlem
Beijing 1
Beijing 2
Delhi/CAS
IS6110 ﬁngerprint Spoligotype embC embA EMB Genotype
2941 bp, g>C
2941 bp, g>C
2941 bp, g>C
2941 bp, g>C
2941 bp, g>C
2213, g>A
2213, g>A
228, c>T (silent)
228, c>T (silent)
228, c>T (silent)
228, c>T (silent)
228, c>T (silent)
228, c>T (silent)
228, c>T (silent)
228, c>T (silent)
228, c>T (silent)
228, c>T (silent)
228, c>T (silent)
228, c>T (silent)
228, c>T (silent)
228, c>T (silent)
228, c>T (silent)
228, c>T (silent)
228, c>T (silent)
228, c>T (silent)
228, c>T (silent)
114, a>G (silent), 228, c>T (silent)
114, a>G (silent), 228, c>T (silent)
114, a>G (silent), 228, c>T (silent)
114, a>G (silent), 228, c>T (silent)
114, a>G (silent), 228, c>T (silent)
114, a>G (silent), 228, c>T (silent)
114, a>G (silent), 228, c>T (silent)
114, a>G (silent), 228, c>T (silent)
114, a>G (silent), 228, c>T (silent)
Res
Res
Sus
Sus
Sus
Res
Sus
Sus
Res
Res
Res
Sus
Sus
Res
Res
Sus
Res
Res
Res
Res
Res
Sus
Sus
Res
Res
Res
Res
Res
Res
Res
Res
Res
Res
Res
Res
Res
Sus
Sus
Res
Res
Res
Res
Res
Res
Res
Res
Figure 3. IS6110 DNA ﬁngerprint and spoligotype patterns as well as phylogenetic informative polymorphisms in embA and embC of the 46 strains investigated. The position of each
IS6110 band is normalized, so that banding patterns of all strains are mutually comparable. The strains’ genotypes are ordered in a dendrogram based on the similarity of their IS6110
DNA ﬁngerprint patterns. EMB, ethambutol; Res, resistant; Sus, susceptible.
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 To further analyse the signiﬁcance of Arg738Gln as a resistance-
mediating SNP or phylogenetic marker onward sequencing work
has been performed (see next paragraph).
Further veriﬁcation of putative resistance-mediating
mutations by analysis of 106 additional strains
Theabovesectionalreadydemonstrated that SNPs arenot necess-
arily involved in the development of resistance. Therefore we
extended the investigation of selected mutations to 106 strains
(104 ethambutol susceptible and 2 ethambutol resistant) from a
population-based study collected in Hamburg during 2007. The
population structure of these strains is highly diverse with an
overall cluster rate of  20% (21 strains in nine clusters). The
majority of strains belong to the Haarlem genotype (n¼23), fol-
lowed by strains of the Beijing (n¼14), East African Indian (n¼7),
Latin American Mediterranean (n¼5), Cameroon (n¼4) and Delhi/
CAS (n¼4) genotypes. The remaining 49 strains belong to various
other genotypes or could not be allocated to previously described
M. tuberculosis complex phylogenetic lineages.
First of all, the mutation at embCArg738Gln was chosen to be
screened in the panel of the above-mentioned strains. Four
strains were found to have mutations in embC at codon 738,
with only one of these an ethambutol-resistant strain,
suggesting that this mutation may be a phylogenetic marker
rather than associated directly with ethambutol resistance. To
test this hypothesis, IS6110 DNA ﬁngerprint and spoligotyping
patterns of the strains were compared. The analysis revealed
that all strains belonging to the Delhi/CAS genotype carry the
embCArg738Gln mutation while strains of all other genotypes
do not, irrespective of being susceptible or resistant to ethambu-
tol. Hence it can be concluded that embC738 is a phylogenetic
SNP for the Delhi/CAS genotype instead of an ethambutol resist-
ance marker.
For veriﬁcation of the other embCAB mutations occurring in
ethambutol-resistant strains only, the embCA intergenic region
(nucleotides 28, 212, 216, 225 and 232) as well as the
embB hotspot region (codons 306–497, namely codons 328,
354, 378, 402, 404, 450 and 454) have been sequenced in the
106 additional strains as well. Sequence analyses showed that
none of the susceptible strains analysed in the control panel
carried a mutation in any of those positions, conﬁrming a role
for the respective SNPs in ethambutol resistance development.
In addition, IS6110 DNA ﬁngerprint and spoligotyping analyses
of the ethambutol-resistant strains revealed that those
mutations analysed occurred in strains belonging to various gen-
otypes (when occurring in more than one strain), further afﬁrm-
ing their potential role in ethambutol resistance mediation (data
not shown).
Discussion
Mutations in embB306 were found to be associated with etham-
butol resistance in previous studies and polymorphisms in this
codon are suggested as molecular markers for the rapid detec-
tion of ethambutol-resistant isolates.
3,4,6 However, between
31% and 50% of ethambutol-resistant clinical isolates have no
mutation in the embB306 region suggesting a role for variations
in other parts of the embCAB operon or other genomic regions for
the development of ethambutol resistance. In this study we
demonstrate that a high proportion (91.2%) of the 34
ethambutol-resistant strains without an embB306 polymorph-
ism had other mutations in the remaining embCAB operon.
Overall, we identiﬁed 18 non-synonymous mutations in 15 dis-
tinct codons of the embCAB operon that were exclusively found
in the ethambutol-resistant strains but not in the ethambutol-
susceptible control isolates.
The majority of mutations occurred in embB, supporting the
idea that mutations in this gene play a key role in the develop-
ment of ethambutol resistance. A total of 24 ethambutol-
resistant strains investigated carried at least one non-
synonymous mutation in embB. In accordance with previous
studies, multiple mutations resulting in two or three different
amino acid exchanges were identiﬁed in codons embB406 and
embB497 representing additional hot spots for mutation
besides embB306.
3,13–15
The observation that multiple mutations affect the same
codon resulting in different amino acid replacements is one
example of positive Darwinian selection by antibiotic pressure.
In a previous study, strains with non-synonymous mutations in
embB406 and embB497 were correlated with high ethambutol
MICs (≥30 mg/L) comparable to those for organisms carrying
embB306 mutations.
2,7
In the current study, further mutations were detected in
embB codons 74, 328, 354, 378, 402, 404, 450 and 454. To
our knowledge the polymorphisms at codons 74, 402, 404,
450 and 454 have not been described previously. Sequence vari-
ations in embB354 have already been reported before, but in
contrast to our study a replacement of aspartic acid by alanine
instead of asparagine was observed.
8,16 The mutations at
codons 328 and 378 have also been described previously.
9,15,16
Since all mutations located in the embB hotspot region (codons
306–497) have not been detected in the panel of ethambutol-
susceptible control strains, they possibly play a role in ethambutol
resistance development.
Few publications provide data about the correlation between
ethambutol MICs and these less frequent distinct mutations. The
ethambutol MIC for a mutant carrying a mutation at codon 354
(Asp Ala) was shown to be 20 mg/L,
8 while a mutation at
codon embB328 has been shown to yield an ethambutol MIC
ranging between 20 and 30 mg/L.
8,15 For strains harbouring a
Glu378Ala amino acid exchange, an ethambutol MIC of 2 mg/L
has previously been determined.
9 These MIC values were
obtained from the analysis of small numbers of strains, carrying
additional mutations, which might also be responsible for the
MIC increase.
It is noticeable that in the current study the majority of the
detected mutations were concentrated in a small region of
 570 bp in the embB gene. This region of the EmbB protein,
including the hot spot codons 306, 406 and 497, is predicted
to be the recognition site of the enzyme.
17 Only two strains
had mutations in embB outside the binding site, but these
strains carried additional mutations. These data suggest that
only mutations located in the recognition site are associated
with ethambutol resistance. Structural changes in the enzyme,
caused by mutations in the recognition site, may prevent
binding of ethambutol leading to resistance development. The
ﬁnding that mutations in ethambutol-resistant clinical isolates
without an embB306 mutation were concentrated in a
Ethambutol resistance conferred by embCAB mutations
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  570 bp encompassing region has practical implications for TB
diagnostics. Analysing this part of the embB gene would probably
enhance the sensitivity for the detection of ethambutol-resistant
isolates.
In two previous studies,
5,18 we investigated a total of 150
ethambutol-resistant strains for variation in the embB306
region. Overall 72.7% of the ethambutol-resistant isolates
could be detected by sequence variations in embB306. Addition-
ally, seven strains were found to have other mutations (codons
319, 328, 332 and 334) in the analysed embB fragment. A
short extension of the sequence analysis to a  600 bp embB
fragment (codons 297–497) would have enhanced the overall
sensitivity of the molecular analysis for detection of ethambutol
resistance to 93.3%, which is comparable to the data described
for other ﬁrst-line drugs such as isoniazid, rifampicin or
pyrazinamide.
14
However, considering the overall broad spectrum of observed
mutations, it will be necessary to validate the potential of par-
ticular mutations to confer (alone or in combination) signiﬁcant
levels of ethambutol resistance by further MIC measurements
on more strains. This is especially important in light of the
increasing usage of molecular tests for the detection of drug
resistance in high-incidence settings.
Interestingly, mutations in embC and embA occurred rarely
and in most cases were combined with mutations in embB,
suggesting that mutations in these genes are less important
for ethambutol resistance. Apparently the arabinosyltransferases
EmbC and EmbA are less susceptible to the inhibiting effect of
ethambutol.
19–22 The differential mode of action of ethambutol
on the Emb proteins can be explained by their involvement in
different pathways. While EmbC is involved in the formation of
arabinan in lipoarabinomannan, the enzymes EmbA and EmbB
participate in the synthesis of arabinan in arabinogalactan.
23,24
The reason for the lower susceptibility of EmbA in comparison
with EmbB, although participating in the same biosynthetic
pathway, is not clear. It can be speculated that both Emb pro-
teins function as a dimer and EmbB is the more important part
of this dimer or that EmbB compensates an inhibiting effect of
ethambutol on EmbA.
24
The detected mutations in embC were located in codons 270
and 406 and in two strains in 738. To our knowledge the
mutation in embC406 has not been described so far. No other
mutations were found in this strain suggesting that sequence
variations in embC406 may confer an ethambutol resistance
phenotype. The mutations in embC270 and embC738 are
already known from previous studies.
9,15,25,26 In one study, an
ethambutol MIC of 40 mg/L for a strain carrying a mutation at
codon 738 was reported.
15 Since this strain had additional
mutations (e.g. embB306) it is unclear whether embC738 actu-
ally contributes to the resistance phenotype. The additional
sequence analysis performed in this study resulted in three sus-
ceptible strains and one resistant strain carrying the embC738
mutation. The fact that all of these strains belong to the Delhi/
CAS genotype and that strains belonging to other genotypes
do not carry the embC738 mutation, irrespective of being sus-
ceptible or resistant to ethambutol, clearly demonstrates that
this mutation is a newly identiﬁed phylogenetic marker instead
of being associated with ethambutol resistance.
The strain carrying a mutation in embC270 was found to have
additional mutations. A poor correlation between embC270
mutation and the degree of ethambutol resistance has been
observed previously.
2,9,25,26 As varying results for ethambutol
MIC determination among embC270 mutant strains carrying
additional mutations in embB have been reported, it is not
clear if there is an additive effect. The combination of
embB306 and embC270 mutations may increase the ethambu-
tol MIC,
9,25,26 but further investigations are necessary.
Mutations in embA were detected in codons 468, 576 and
639. None of them has been described previously. The mutations
in codons 468 and 639 occurred together in one isolate that had
additional mutations in embC and embB. The strain showing the
mutation in codon 576 carried further mutations in the inter-
genic region and in embB. As the embA mutations appeared
only in combination with other mutations their relevance for
ethambutol resistance is unclear and needs to be further
investigated.
Novel mutations in the embC–embA intergenic region were
also found. Besides the known nucleotide variations, which
were located 12 and 16 bp upstream of the embA gene,
mutations were detected at positions 28, 225 and 232 bp.
15
The nucleotide substitutions at positions 28, 212 and 216 bp
are located within/adjacent to a predicted TATA box.
15 Mutations
in this promoter region may be involved in the development of
ethambutol resistance by increasing the gene expression of
embA and/or embB. With respect to the additional sequence
analysis of the embCA intergenic region none of the susceptible
strains analysed carried a mutation at those speciﬁc positions.
Therefore, these results strengthen the hypothesis that those
mutations, alone or in combination, contribute to the develop-
ment of ethambutol resistance.
In addition to the embC738 mutation, we identiﬁed further
genotype-speciﬁc mutations in the embC and embA genes. In
embA two synonymous mutations were associated with the
Beijing genotype and a sub-group of the Beijing genotype,
respectively. The mutation in embC at codon 981 was already
mentioned previously and suggested to be a phylogenetic
rather than a resistance marker.
2,15 A total of eight ethambutol-
resistant isolates were without non-synonymous mutations
and three of these did not have any mutations in the entire
embCAB operon. In these cases, mutations in other so far
unknown genes might be involved in the development of
ethambutol resistance.
In conclusion, this study demonstrates a strikingly high
variety of mutations in embCAB that might have a potential
role in the development of ethambutol resistance in clinical
M. tuberculosis complex isolates and may be valuable markers
for the identiﬁcation of strains belonging to different genotypes.
Our results clearly demonstrate that a short stretch of the embB
gene encompasses the most important mutation hot spots
(codons 306, 406 and 497). Although more data from other
high TB drug resistance settings are required, this mutational
hot spot region is of high interest for inclusion in molecular
assays.
Our data also demonstrate that results from molecular
association studies should be interpreted carefully. Large, well-
chosen control groups are necessary to allow conclusions con-
cerning a possible involvement in development of resistance. In
addition, further validation should be sought by in vitro selection
experiments or by generation of isogenic mutants via allelic
exchange.
Plinke et al.
1366
 
b
y
 
g
u
e
s
t
 
o
n
 
F
e
b
r
u
a
r
y
 
8
,
 
2
0
1
1
j
a
c
.
o
x
f
o
r
d
j
o
u
r
n
a
l
s
.
o
r
g
D
o
w
n
l
o
a
d
e
d
 
f
r
o
m
 Acknowledgements
We would like to thank I. Radzio, T. Ubben, L. Dost and P. Vock for
excellent technical assistance.
Funding
This work was supported by the European Union TM-REST (FP7-202145)
and the TB-PAN-NET (FP7-223681) projects.
Transparency declarations
None to declare.
References
1 WHO. Anti-Tuberculosis Drug Resistance in the World. Report Number 4.
Geneva: WHO, 2008.
2 Sreevatsan S, Stockbauer KE, Pan X et al. Ethambutol resistance in
Mycobacterium tuberculosis: critical role of embB mutations. Antimicrob
Agents Chemother 1997; 41: 1677–81.
3 Lee AS, Othman SN, Ho YM et al. Novel mutations within the embB
gene in ethambutol-susceptible clinical isolates of Mycobacterium
tuberculosis. Antimicrob Agents Chemother 2004; 48: 4447–9.
4 Mokrousov I, Otten T, Vyshnevskiy B et al. Detection of embB306
mutations in ethambutol-susceptible clinical isolates of Mycobacterium
tuberculosis from northwestern Russia: implications for genotypic
resistance testing. J Clin Microbiol 2002; 40: 3810–3.
5 Plinke C, Rusch-Gerdes S, Niemann S. Signiﬁcance of mutations in
embB codon 306 for prediction of ethambutol resistance in clinical
Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother
2006; 50: 1900–2.
6 van Rie A, Warren R, Mshanga I et al. Analysis for a limited number of
gene codons can predict drug resistance of Mycobacterium tuberculosis in
a high-incidence community. J Clin Microbiol 2001; 39: 636–41.
7 Saﬁ H, Sayers B, Hazbon MH et al. Transfer of embB codon 306
mutations into clinical Mycobacterium tuberculosis strains alters
susceptibility to ethambutol, isoniazid, and rifampin. Antimicrob Agents
Chemother 2008; 52: 2027–34.
8 Starks AM, Gumusboga A, Plikaytis BB et al. Mutations at embB codon
306 are an important molecular indicator of ethambutol resistance in
Mycobacterium tuberculosis. Antimicrob Agents Chemother 2009; 53:
1061–6.
9 Srivastava S, Garg A, Ayyagari A et al. Nucleotide polymorphism
associated with ethambutol resistance in clinical isolates of
Mycobacterium tuberculosis. Curr Microbiol 2006; 53: 401–5.
10 Wu XQ, Liang JQ, Zhang JX et al. Detection and evaluation of the
mutations of embB gene in ethambutol-susceptible and resistant
Mycobacterium tuberculosis isolates from China. Chin Med J (Engl)
2005; 118: 1739–41.
11 Van Embden JD, Cave MD, Crawford JT et al. Strain identiﬁcation of
Mycobacterium tuberculosis by DNA ﬁngerprinting: recommendations
for a standardized methodology. J Clin Microbiol 1993; 31: 406–9.
12 Kamerbeek J, Schouls L, Kolk A et al. Simultaneous detection and
strain differentiation of Mycobacterium tuberculosis for diagnosis and
epidemiology. J Clin Microbiol 1997; 35: 907–14.
13 Ahmad S, Jaber AA, Mokaddas E. Frequency of embB codon 306
mutations in ethambutol-susceptible and -resistant clinical Mycobacterium
tuberculosis isolates in Kuwait. Tuberculosis (Edinb) 2007; 87:1 2 3–9 .
14 Parsons LM, Somoskovi A, Urbanczik R et al. Laboratory diagnostic
aspects of drug resistant tuberculosis. Front Biosci 2004; 9: 2086–105.
15 Ramaswamy SV, Amin AG, Goksel S et al. Molecular genetic analysis
of nucleotide polymorphisms associated with ethambutol resistance in
human isolates of Mycobacterium tuberculosis. Antimicrob Agents
Chemother 2000; 44: 326–36.
16 Sekiguchi J, Miyoshi-Akiyama T, Augustynowicz-Kopec E et al.
Detection of multidrug resistance in Mycobacterium tuberculosis. J Clin
Microbiol 2007; 45: 179–92.
17 Zhang N, Torrelles JB, McNeil MR et al. The Emb proteins of
mycobacteria direct arabinosylation of lipoarabinomannan and
arabinogalactan via an N-terminal recognition region and a C-terminal
synthetic region. Mol Microbiol 2003; 50: 69–76.
18 Plinke C, Cox HS, Kalon S et al. Tuberculosis ethambutol resistance:
concordance between phenotypic and genotypic test results.
Tuberculosis (Edinb) 2009; 89: 448–52.
19 Deng L, Mikusova K, Robuck KG et al. Recognition of multiple effects
of ethambutol on metabolism of mycobacterial cell envelope.
Antimicrob Agents Chemother 1995; 39: 694–701.
20 Goude R, Amin AG, Chatterjee D et al. The critical role of embC in
Mycobacterium tuberculosis. J Bacteriol 2008; 190: 4335–41.
21 Khoo KH, Douglas E, Azadi P et al. Truncated structural variants of
lipoarabinomannan in ethambutol drug-resistant strains of
Mycobacterium smegmatis. Inhibition of arabinan biosynthesis by
ethambutol. J Biol Chem 1996; 271: 28682–90.
22 Mikusova K, Slayden RA, Besra GS et al. Biogenesis of the
mycobacterial cell wall and the site of action of ethambutol.
Antimicrob Agents Chemother 1995; 39: 2484–9.
23 Escuyer VE, Lety MA, Torrelles JB et al. The role of the embA and embB
gene products in the biosynthesis of the terminal hexaarabinofuranosyl
motif of Mycobacterium smegmatis arabinogalactan. J Biol Chem 2001;
276: 48854–62.
24 Shi L, Berg S, Lee A et al. The carboxy terminus of EmbC from
Mycobacterium smegmatis mediates chain length extension of the
arabinan in lipoarabinomannan. J Biol Chem 2006; 281: 19512–26.
25 Jadaun GP, Das R, Upadhyay P et al. Role of embCAB gene mutations
in ethambutol resistance in Mycobacterium tuberculosis isolates from
India. Int J Antimicrob Agents 2009; 33: 483–6.
26 Srivastava S, Ayyagari A, Dhole TN et al. emb nucleotide
polymorphisms and the role of embB306 mutations in Mycobacterium
tuberculosis resistance to ethambutol. Int J Med Microbiol 2009; 299:
269–80.
Ethambutol resistance conferred by embCAB mutations
1367
JAC
 
b
y
 
g
u
e
s
t
 
o
n
 
F
e
b
r
u
a
r
y
 
8
,
 
2
0
1
1
j
a
c
.
o
x
f
o
r
d
j
o
u
r
n
a
l
s
.
o
r
g
D
o
w
n
l
o
a
d
e
d
 
f
r
o
m
 